戻る Agenda
Session 6: How Can Changes in Protocol Development and Design Impact DEI?
Session Chair(s)
Alissa Goodale, DrMed
Regulatory Executive Director
Genentech, A Member of the Roche Group, United States
Laura Meloney, MPH, MSc
Program Director
Multi-Regional Clinical Trials Center of Brigham & Women's Hospital and Harvard, United States
This session will review the essential elements of protocol development and design and how to infuse concepts and principles of diversity, equity, and inclusion throughout. Novel and innovative clinical trial elements that may enable and enhance DEI in clinical research will be discussed. In addition, DEI concepts that the institutional review boards and independent ethics committees (IRB/IECs) should be evaluating when reviewing protocols, may also be reviewed.
Learning Objective : At the conclusion of this session, participants should be able to:
- Apply DEI principles in the development and design process of clinical research protocols
- Explain how novel, innovative clinical trial elements can enable and enhance DEI in clinical research
Speaker(s)
Speaker
Jonathan David Jackson, PhD
Massachusetts General Hospital, Harvard Medical School, United States
Assistant Professor, Neurology, Executive Director,